A number of other analysts have also issued reports on INF. Numis Securities reaffirmed an add rating on shares of Informa in a research report on Wednesday, July 25th. Barclays reaffirmed an overweight rating and set a GBX 920 ($12.02) target price on shares of Informa in a research report on Tuesday, June 19th. Peel Hunt reaffirmed a hold rating on shares of Informa in a research report on Tuesday, July 3rd. Berenberg Bank reiterated a buy rating and issued a GBX 900 ($11.76) price target on shares of Informa in a research note on Wednesday, August 1st. Finally, Shore Capital reiterated a buy rating on shares of Informa in a research note on Friday, July 20th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of GBX 862.75 ($11.27).
Shares of LON INF traded down GBX 10 ($0.13) during midday trading on Wednesday, reaching GBX 738.40 ($9.65). 2,065,547 shares of the company’s stock were exchanged, compared to its average volume of 3,640,000. Informa has a 52-week low of GBX 624.50 ($8.16) and a 52-week high of GBX 773 ($10.10).
The business also recently declared a dividend, which was paid on Friday, September 14th. Shareholders of record on Thursday, August 9th were issued a GBX 7.05 ($0.09) dividend. The ex-dividend date of this dividend was Thursday, August 9th. This represents a dividend yield of 0.86%.
Informa Company Profile
Informa plc engages in business intelligence, academic publishing, and knowledge and events businesses worldwide. The company operates through Academic Publishing, Business Intelligence, Global Exhibitions, and Knowledge & Networking segments. The Academic Publishing segment publishes academic books and journals in print and digital formats for university libraries and departments, specialist research institutions, and individuals in the areas of humanities and social sciences, science, technology, and medicine.
Further Reading: Call Option
Receive News & Ratings for Informa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Informa and related companies with MarketBeat.com's FREE daily email newsletter.